Novo Nordisk (NVO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Diabetes/Obesitysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 12/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.99% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Is Novo Nordisk (CPSE:NOVO B) Cheap After Lillys EMA Win Raised GLP 1 Pressure?
- Is Novo Nordisk (CPSE:NOVO B) Facing A Bigger Threat In Europe?
- Novo Nordisk and Eli Lilly Just Got Some Fantastic News
- Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
- Lilly’s Foundayo wins EMA panel backing for obesity and type 2 diabetes
- European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
- Novo Nordisk (NVO) Could Be 63% Undervalued Following Its Share Buyback
- Is Novo Nordisk (NYSE:NVO) A Long Term Value Opportunity Now?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. — N Engl J Med 2023 Sep 21 PMID 37622681
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Novo Nordisk.
Full NVO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.